Legalization advocates have long argued that marijuana represents a potentially effective treatment option for chronic pain and could serve as an alternative to opioid-based painkillers—and according to a new scientific meta-analysis, they may be onto something.
Cresco Labs has announced non-dilutive debt financing of US$100 million, with an option to increase to US$200 million.
InMed Pharmaceuticals has isolated the rare cannabinoid, cannabinol, in two cannabinoid-based drugs currently in clinical trials.
The U.S. Food and Drug Administration is claiming that CBD poses significant risks to the human liver. Nonsense.
As Canadian cannabis retailers gather momentum, Choom Holdings provides investors with a very attractive value proposition.
Aphria disappointed slightly on Q2 revenue and its stock is trading lower. Investors may see a buying opportunity here.
Fire & Flower Holdings is Canada's new retailing leader in stores as it reports opening its 46th cannabis store.
The Food and Drug Administration (FDA) recently announced a policy change that will expedite the marketing of marijuana testing devices if they’re used for certain purposes.
The new cannabis store licensing system has commenced in Ontario. Total retail cannabis stores could multiply by nearly a factor of 10 in 2020.